BlackRock’s Grace Therapeutics GRCE Stock Holding History

BlackRock’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$85.2K	Buy	+37,535	New	+$104K	﹤0.01%	5040
2023 Q1	–	Sell	-10	Closed	-$31	–	5745
2022 Q4	$31	Buy	+10	New	+$29	﹤0.01%	5746

Other funds holding GRCE

Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock's GRCE Position: Q2 2026 in Review

BlackRock opened a new position in Grace Therapeutics (GRCE) in Q2 2026: 37,535 shares worth $85.2K. The stake represents ﹤0.01% of the portfolio and ranks #5040 among its holdings. This is a return to the name: BlackRock previously reported a position in GRCE as recently as Q4 2022.

BlackRock first reported a position in GRCE in Q4 2022 and has held it in 2 quarters since. 33 funds tracked by Wall St. Rank hold GRCE as of Q2 2026.

BlackRock held 37,535 shares of Grace Therapeutics worth $85.2K as of Q2 2026.
Grace Therapeutics was a new BlackRock position in Q2 2026.
Grace Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5040 holding.
BlackRock first reported a position in Grace Therapeutics in Q4 2022 and has held it in 2 quarters since.
33 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.